RU2278658C2 - Рецептура на основе гепарина - Google Patents

Рецептура на основе гепарина Download PDF

Info

Publication number
RU2278658C2
RU2278658C2 RU2002135623/15A RU2002135623A RU2278658C2 RU 2278658 C2 RU2278658 C2 RU 2278658C2 RU 2002135623/15 A RU2002135623/15 A RU 2002135623/15A RU 2002135623 A RU2002135623 A RU 2002135623A RU 2278658 C2 RU2278658 C2 RU 2278658C2
Authority
RU
Russia
Prior art keywords
component
formulation
lipid
molecular weight
lipid component
Prior art date
Application number
RU2002135623/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2002135623A (ru
Inventor
Йорг РОЗЕНБЕРГ (DE)
Йорг Розенберг
Йорг БРАЙТЕНБАХ (DE)
Йорг Брайтенбах
Дитер ХЕРР (DE)
Дитер ХЕРР
Фолькер ЛАУКС (DE)
Фолькер Лаукс
Роберт ХЕГЕР (DE)
Роберт ХЕГЕР
Original Assignee
Басф Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Басф Акциенгезельшафт filed Critical Басф Акциенгезельшафт
Publication of RU2002135623A publication Critical patent/RU2002135623A/ru
Application granted granted Critical
Publication of RU2278658C2 publication Critical patent/RU2278658C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Materials For Medical Uses (AREA)
RU2002135623/15A 2000-05-30 2001-05-29 Рецептура на основе гепарина RU2278658C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10026699.1 2000-05-30
DE10026699A DE10026699A1 (de) 2000-05-30 2000-05-30 Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage

Publications (2)

Publication Number Publication Date
RU2002135623A RU2002135623A (ru) 2004-07-10
RU2278658C2 true RU2278658C2 (ru) 2006-06-27

Family

ID=7644040

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002135623/15A RU2278658C2 (ru) 2000-05-30 2001-05-29 Рецептура на основе гепарина

Country Status (13)

Country Link
US (1) US7393840B2 (enExample)
EP (1) EP1284717B1 (enExample)
JP (1) JP5198708B2 (enExample)
CN (1) CN100391440C (enExample)
AT (1) ATE349202T1 (enExample)
AU (1) AU2001266033A1 (enExample)
BR (1) BR0111257A (enExample)
CA (1) CA2409828C (enExample)
DE (2) DE10026699A1 (enExample)
ES (1) ES2278750T3 (enExample)
NO (2) NO20025755D0 (enExample)
RU (1) RU2278658C2 (enExample)
WO (1) WO2001091729A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359945C (en) * 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
DE50105650D1 (de) * 2000-12-16 2005-04-21 Aventis Pharma Gmbh Verwendung von niedermolekularen heparin zur behandlung von osteoarthrose
GB0205868D0 (en) * 2002-03-13 2002-04-24 Univ Nottingham Polymer composite with internally distributed deposition matter
JP4416664B2 (ja) * 2002-05-03 2010-02-17 マサチューセッツ・インスティテュート・オブ・テクノロジー Δ４，５グリクロニダーゼおよびその使用
SE0201922D0 (sv) * 2002-06-20 2002-06-20 Ltp Lipid Technologies Provide Koagulationshindrande komposition (Anticoagulant Composition)
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2005042623A1 (en) * 2003-10-23 2005-05-12 University Of Nottingham Preparing active polymer extrudates
EP1711595B1 (en) * 2003-12-02 2007-11-21 Universiteit Gent Use of polysulphated alginate in cellular matrices
EP1537871A1 (en) * 2003-12-04 2005-06-08 Aventis Pharma S.A. Enoxaparin for the treatment of cancer
US7563780B1 (en) * 2004-06-18 2009-07-21 Advanced Cardiovascular Systems, Inc. Heparin prodrugs and drug delivery stents formed therefrom
JP5258144B2 (ja) * 2004-12-21 2013-08-07 株式会社分子生理化学研究所 吸収性の改善された固形状のコエンザイムｑ１０経口製剤の製造方法
US7691830B2 (en) * 2005-02-17 2010-04-06 Clive Elson Method and composition for treatment of a mucosal tissue disorder
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
GB0812742D0 (en) * 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
US20110305658A1 (en) * 2008-12-11 2011-12-15 L'oreal S.A. Lengthening mascara composition
WO2010113176A2 (en) * 2009-03-31 2010-10-07 Reliance Life Sciences Pvt. Ltd. Novel copolymers for controlled release delivery system
ES2363964B1 (es) 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
WO2011088418A2 (en) * 2010-01-15 2011-07-21 Mount Sinai School Of Medicine Inhibition of tnf-alpha induced activation of nfkb by pentosan polysulfate
WO2014142938A1 (en) * 2013-03-15 2014-09-18 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
US10897918B1 (en) * 2013-03-15 2021-01-26 Mccormick & Company, Incorporated Extrusion encapsulation with narrow particle size and shape distribution, high solubility, and low surface oil
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
JP6877996B2 (ja) * 2016-12-27 2021-05-26 小林製薬株式会社 外用組成物
JP6877997B2 (ja) * 2016-12-27 2021-05-26 小林製薬株式会社 外用組成物
WO2019236453A1 (en) * 2018-06-03 2019-12-12 Glycomira Therapeutics, Inc. Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and /or chemotherapy
US20210069237A1 (en) * 2019-09-09 2021-03-11 Harrow Ip, Llc Pharmaceutical compositions comprising heparinoids and methods for preparing thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656161A (en) * 1983-08-27 1987-04-07 Basf Aktiengesellschaft Increasing the enteral absorbability of heparin or heparinoids
RU2139046C1 (ru) * 1994-11-22 1999-10-10 Бракко Рисерч С.А. Микрокапсулы, способ изготовления и их применение

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1107041A (en) * 1913-10-25 1914-08-11 Benjamin H Cook Coupling device.
JPS58101311A (ja) * 1981-12-11 1983-06-16 Toshiba Corp 多相電圧電流変換回路
JPS6054313A (ja) * 1983-09-01 1985-03-28 Terumo Corp 腸管吸収性ヘパリン組成物
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
SE9200951D0 (sv) * 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical composition containing a defined lipid system
US5346701A (en) * 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
SE9302135D0 (sv) * 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
AU692506B2 (en) * 1993-11-17 1998-06-11 Ibah, Inc. Transparent liquid for encapsulated drug delivery
DE19531277A1 (de) * 1995-08-25 1997-02-27 Basf Ag Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren
FR2775188B1 (fr) 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
DE69917609T2 (de) * 1998-03-05 2005-06-09 Phares Pharmaceutical Research N.V., Curaçao Arzneimittel und deren verwendung
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656161A (en) * 1983-08-27 1987-04-07 Basf Aktiengesellschaft Increasing the enteral absorbability of heparin or heparinoids
RU2139046C1 (ru) * 1994-11-22 1999-10-10 Бракко Рисерч С.А. Микрокапсулы, способ изготовления и их применение

Also Published As

Publication number Publication date
EP1284717A1 (de) 2003-02-26
AU2001266033A1 (en) 2001-12-11
JP2003534370A (ja) 2003-11-18
CN1450891A (zh) 2003-10-22
WO2001091729A1 (de) 2001-12-06
ATE349202T1 (de) 2007-01-15
US7393840B2 (en) 2008-07-01
DE50111738D1 (de) 2007-02-08
CN100391440C (zh) 2008-06-04
NO20025759D0 (no) 2002-11-29
CA2409828C (en) 2010-08-03
NO20025755D0 (no) 2002-11-29
NO20025759L (no) 2003-01-14
ES2278750T3 (es) 2007-08-16
DE10026699A1 (de) 2001-12-06
BR0111257A (pt) 2003-06-10
JP5198708B2 (ja) 2013-05-15
US20030161884A1 (en) 2003-08-28
EP1284717B1 (de) 2006-12-27
CA2409828A1 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
RU2278658C2 (ru) Рецептура на основе гепарина
EP2258344B1 (en) Solid pharmaceutical dosage form comprising a ritonavir and lopinavir solid dispersion
JP5244102B2 (ja) 薬学的に許容される可溶化組成物及び該組成物を含む薬学的剤形
US8333990B2 (en) Solid pharmaceutical dosage form
JP5240822B2 (ja) 多孔質セルロース凝集体及びその成型体組成物
CA2598827C (en) An hiv protease inhibitor solid dosage formulation for the treatment of hiv/aids under fasting conditions
KR101387249B1 (ko) 물에 난용성인 유효 성분과 중합체의 혼합물을 함유하는제약 조성물
JP2003534369A (ja) 自己乳化性の活性物質配合物およびこの配合物の使用
HU221981B1 (hu) Késleltetett kibocsátású mátrixszemcsék és eljárás előállításukra
JP2010509289A (ja) チロシンキナーゼ阻害剤の経口投与用薬学的剤形
KR20000036066A (ko) 압출성형에 의한 고상 제형의 제조 방법
KR20170040336A (ko) 입자를 포함하는 제제
US9789065B2 (en) Process for producing oral dosage forms with controlled release
KR20170040337A (ko) 포만을 유도하는 방법
AU2003277907A1 (en) Controlled delivery system for bioactive substances
JP5249050B2 (ja) エチルセルロースを含む生物活性組成物
JPH04243819A (ja) 徐放性製剤
WO2024023173A1 (en) Solid pharmaceutical dosage form comprising a bcs class ii drug and a method for producing the same
JP2022139962A (ja) 顆粒、顆粒の製造方法、及び錠剤
Abdul et al. Formulation of Diclofenac Sodium Delayed-Release Disintegrating Tablets
HK1145969B (en) Solid pharmaceutical dosage form comprising a ritonavir and lopinavir solid dispersion

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20140530